The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Ibrutinib and venetoclax upfront for high-risk CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the updated results of combined ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL) patients with high-risk genomics or an age of 65 years or older (NCT02756897). Results suggest that ibrutinib in combination with venetoclax is an effective chemotherapy-free oral regimen for high-risk previously untreated CLL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
